Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108

Related Content

Deals Shaping The Medical Industry, February 2013

Feb 05 2013

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol

Jul 22 2016

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

Jan 28 2017

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Jan 11 2017

Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection

Nov 17 2016

Amgen's Parsabiv Approved With Unusual Postmarketing Requirements

Feb 13 2017

Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road

Jun 20 2016

Marathon Looking To Go The Distance In DMD

Jun 14 2016

Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles

Aug 05 2016

Keeping Track: FDA Approves Epclusa, Designates Four Breakthrough Therapies, Files Burst Of Applications

Jul 04 2016

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

Oct 29 2016

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Feb 10 2017

Canada First To OK Sanofi/Regeneron’s Sarilumab, But Struggle To Differentiate Looms

Feb 01 2017

Related Companies

Marathon Pharmaceuticals LLC

Amgen, Inc.

Synergy Pharmaceuticals, Inc.

Daiichi Sankyo Co., Ltd.

Charleston Laboratories, Inc.

Sarepta Therapeutics, Inc.

ADMA Biologics, Inc.

Biotest AG

Biotest AG

Lipocine Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Bausch Health Companies Inc.

Bausch Health Companies Inc.

Intellipharmaceutics International Inc.

Flexion Therapeutics, Inc.

Aquestive Therapeutics, Inc.

Additional Topics

United States Approvals Complete Response Letters Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window